EA-89
EA-89 is a potent and selective BRD9 inhibitor with antitumor activity. EA-89 is a Ligand for Target Protein for PROTAC. EA-89 can be used to synthesize PROTAC QA-68 (HY-150797).
For research use only. We do not sell to patients.
- Formula: C31H38N4O4S2
- Molecular Weight:594.79
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
|
BRD9 |
In Vitro
EA-89 (0-3.2 μM; 1-7 days) inhibits cell proliferation and expression of BRD9, c-MYC and c-MYB in human leukemia cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SKM-1 cells
-
Concentration:0, 10, 100, 1000 nM
-
Incubation Time:24 h
-
Result:Reduced the levels of c-MYC and c-MYB.
Chemical Information
-
Molecular Weight 594.79
-
Formula C31H38N4O4S2
-
SMILES
CCCN1C=C(C2=CC=C(N(CC3CCNCC3)C=C4C)C4=C2)C5=C(C=C(S5)C(NC6CCS(CC6)(=O)=O)=O)C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
EA-89 Related Classifications
HY-170314 Related Classifications
Powered by Bioz